Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This study found that knocking out the Hars2 gene in mouse cochlear hair cells led to mitochondrial dysfunction and ROS stress, resulting in progressive hearing loss and differential effects on inner and outer hair cells.

This study in Arabidopsis thaliana found that exposure to volatile compounds from Penicillium aurantiogriseum promotes root hair growth through signaling involving RALF22, ethylene, auxin, and photosynthesis, and that RALF22 plays a crucial role in the plants' response to these compounds.

This review outlines the evolution and strategies of drug repurposing, highlighting its transformation from accidental discoveries to a predictive, data-driven discipline through the integration of bioinformatics and artificial intelligence, with notable applications during the COVID-19 pandemic.

This study observed four consanguineous families with congenital atrichia with papular lesions and identified three novel mutations in the hairless gene, which may contribute to the disorder.

This study investigated a patient with spinal and bulbar muscular atrophy who had 68 CAG repeats, revealing early onset and unique symptoms not previously documented in the condition.

In this study, researchers found that during late pregnancy, neuroactive steroid fluctuations increase the number of extrasynaptic GABAA receptors in rat hippocampal cells.

In this first reported case, a 42-year-old female with Parry Romberg Syndrome was treated using hyaluronic acid filler, which the authors suggest may serve as a safe, simple, and cost-effective alternative to more complex surgical methods.

This study observed an increase in hair thickness and reduced hair loss in patients with androgenetic alopecia after treatment with autologous cellular suspension using the Rigenera® system, though further research is needed.

This review analyzes PDRN's molecular mechanisms and therapeutic applications in anti-aging dermatology but reports no new clinical results, highlighting the need for more standardized protocols and long-term evaluations.

This review discusses drug repurposing strategies for rare diseases, highlighting methodologies, achievements, and challenges, but reports no new clinical results.

This review discusses keratin disorders and potential RNA interference therapeutics, reporting no new clinical findings but highlighting the promise of siRNA for future treatments.

This study found enhanced remyelination in the corpus callosum of late pregnant rats compared to virgin and postpartum rats, suggesting a pregnancy-associated promyelinating effect mediated, in part, by the GABA A receptor system.

This study found an association between 'short' CAG repeats in the androgen receptor gene and increased non-random X chromosome inactivation in women with androgenic alopecia.

This study found that the RADA-GHK and RADA-KGHK peptide hydrogels improved wound healing and cell growth without cytotoxicity, suggesting potential for use in skin regeneration.

In this study, researchers identified a cluster of hair-specific keratin-associated protein genes within the 21q22.3 region, revealing a novel transcription mechanism involving TSPEAR/C21orf29 that may bypass typical transcriptional termination sites.

In this study, researchers developed an open-source browser-based tool to enhance the reproducibility and accuracy of SALT score calculations from scalp photos, aimed particularly at assessing partial regrowth in alopecia areata patients on JAK inhibitor therapy.

In this study, researchers found that size polymorphisms in certain hKAP1 genes are linked to the hKAP1.1B and hKAP1.3 genes, arising from intragenic deletions and duplications in Japanese and Caucasian populations.

This study found that rhamnose can restore hair-inducing gene expression in dermal papilla cells and accelerate hair follicle regeneration by promoting the hair cycle into the anagen phase, suggesting its potential therapeutic application for alopecia treatment.

This review synthesizes evidence on how RNA modifications affect wound healing, particularly in skin, bone, and corneal injuries, emphasizing potential therapeutic strategies for burns and trauma in relation to these cellular processes.

This study identifies mutations in the SRD5A3 gene as a cause of a new type of congenital disorder of glycosylation, impacting mental, ophthalmologic, and cerebellar functions.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

Both types of Platelet-Rich Plasma treatments work well for hair loss.

This tool was developed to enhance reproducibility and sensitivity in measuring partial hair regrowth in alopecia areata patients, particularly those undergoing JAK inhibitor therapy, using scalp photographs.

This study provides a narrative review suggesting GLP-1 receptor agonists could optimize metabolic health before conception in women with PCOS, but not necessarily improve fertility outcomes, emphasizing individualized use and the need for further research to confirm their reproductive benefits and safety.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.